Skip to main content
. 2019 Apr 19;2(4):e192589. doi: 10.1001/jamanetworkopen.2019.2589

Table 2. Frequency and Proportion of Treated Patients Receiving Sipuleucel-T.

Study Year No. Receiving Any Therapy (nā€‰=ā€‰7272)a No. (%) Receiving Sipuleucel-T Therapy (nā€‰=ā€‰730)
2010 643 4 (0.6)
2011 710 76 (10.7)
2012 918 139 (15.1)
2013 1110 132 (11.9)
2014 1393 147 (10.6)
2015 1421 139 (9.8)
2016 1077 93 (8.6)
a

Includes any treatment for metastatic castration-resistant prostate cancer (sipuleucel-T, abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, or radium 223).